Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Study on the Mechanism of Acquired Resistance of Entrectinib
A clinical trial update from Fudan University studying how resistance to entrectinib develops in ROS1 fusion-positive non-small cell lung ca…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer [NA]
Clinical trial update for NutriCare Plus, a medically tailored meal intervention, being studied in patients with various forms of lung cance…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI [Phase 2]
Phase 2 clinical trial update evaluating sequential chemotherapy with befotertinib in non-small cell lung cancer patients who have developed…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial evaluating neoadjuvant therapy for resectable stage IB-III non-squamous non-small cell lung cancer, comparing IBI-3…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
A real-world study of IBI351 for KRAS G12C-positive non-small cell lung cancer in China, with the trial status listed as not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update describes a single-arm, open-label Phase I/II study of GFH276 in patients with RAS-mutant advanced solid tumors, …
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
Real-world study assessing taletrectinib in advanced ROS1-positive non-small cell lung cancer after progression on entrectinib; the trial st…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial [Phase 3]
A Phase 3 randomized trial protocol evaluating the efficacy and safety of combining microwave ablation with Huaier Granules in patients with…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer [NA]
A recruiting clinical trial evaluating adding pemetrexed to a third-generation EGFR tyrosine kinase inhibitor (e.g., osimertinib) versus the…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) [Phase 2]
Phase 2 single-arm trial evaluating the combination of Datopotamab Deruxtecan, carboplatin, and pembrolizumab for treatment-naive brain meta…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. [Phase 2, Phase 3]
An update on a Phase 2/Phase 3 clinical trial evaluating SI-B001 in combination with Osimertinib for recurrent metastatic non-small cell lun…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer [Phase 2]
A Phase 2 trial evaluating Olvimulogene Nanivacirepvec with platinum-doublet chemotherapy and physician-chosen immune checkpoint inhibitor v…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors [Phase 2]
Phase 2 clinical trial update for SI-B003 and the BL-B01D1+SI-B003 combination in locally advanced or metastatic non-small cell lung cancer,…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy [Phase 3]
Phase 3 clinical trial update evaluating cobolimab + dostarlimab + docetaxel versus dostarlimab + docetaxel and docetaxel alone in advanced …
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
A clinical trial update describing the collection and analysis of tissue samples from patients undergoing surgery for non-small cell lung ca…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. [Phase 2]
Phase 2 clinical trial evaluating SI-B001 in combination with chemotherapy for EGFR/ALK wild-type recurrent or metastatic non-small cell lun…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating SI-B001 with or without SI-B003 and chemotherapy for locally advanced or metastatic non-small cell lung cancer …
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC [Phase 1, Phase 2]
Clinical trial update describing a Phase 1b/Phase 2 study evaluating the combination of Alectinib and Cobimetinib in adults with advanced AL…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating EXL01 in combination with Nivolumab for advanced non-small cell lung cancer refractory to immunothe…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Osimertinib for Advanced EGFR-positive NSCLC Patients
A clinical trial is evaluating Osimertinib for advanced EGFR-positive non-small cell lung cancer and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) [Phase 1, Phase 2]
This clinical trial update reports Eli Lilly's KRAS G12C inhibitor LY3537982 is being studied in Phase 1/2 trials across multiple KRAS G12C-…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy [Phase 2]
A Phase 2 clinical trial is evaluating sacituzumab govitecan in combination with furmonertinib as second-line therapy for EGFR-mutant advanc…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) [Phase 2]
Phase 2 clinical trial update on lorlatinib for patients with metastatic ROS1-positive non-small cell lung cancer after failure of first-lin…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)
Clinical trial update describing a first-line strategy for metastatic non-small cell lung cancer using nivolumab plus ipilimumab in combinat…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial [Phase 1, Phase 2]
Phase 1/2 randomized trial evaluating immunodynamics-guided optimization of individualized immunochemotherapy for advanced driver-negative n…